[ad_1]
A coronavirus vaccine developed by Chinese Sinovac Biotech was 78% effective in an advanced stage Brazilian trial without a severe case of Covid-19, researchers said on Thursday, although a lack of data details raised concerns. calls for more transparency, Reuters reports.
The results of the trial, closely watched by developing countries relying on the vaccine to start mass vaccines to help end a raging pandemic, were lower than preliminary results from Turkish researchers and lacked detailed data. provided on American and European vaccines.
The director of the Brazilian biomedical center Butantan, a research and production partner of Sinovac, said detailed results were being submitted to health regulator Anvisa as part of a request for emergency use of the vaccine.
“One thing is a presentation at a press conference. It’s another thing to get the data and analyze it, which Anvisa will do, ”said Cristina Bonorino, who sits on the scientific committee of the Brazilian Society of Immunology. “If that’s what they say, it’s a great result,” she added.
Brazil and Indonesia, which respectively have the most Covid-19 cases in Latin America and Southeast Asia, are preparing to roll out the vaccine, called CoronaVac, this month. Turkey, Chile, Singapore, Ukraine and Thailand also have supply agreements with Sinovac.
Although CoronaVac’s efficacy is lower than the 95% vaccine success rate of Moderna Inc or Pfizer Inc with its partner BioNTech SE, it is easier to transport and can be stored at normal refrigerator temperatures.
The 78% efficacy rate is also well above the benchmark of 50% to 60% set by global health authorities for vaccines in development at the start of the pandemic, given the urgent need.
[ad_2]
Source link